|
Hypertensive disease
|
0.070 |
Biomarker
|
group |
BEFREE |
Hypertension (86% vs. 70%, P < 0.001), diabetes (68% vs. 55%, P = 0.001) and statin use (61% vs. 45%, P < 0.001) were significantly greater in the ACEI/ARB group.
|
31626938 |
2020 |
|
Hypertensive disease
|
0.070 |
Biomarker
|
group |
BEFREE |
<b>Methods:</b> Eighty-five outpatients with hypertension who took an ARB except irbesartan more than 3 months were assigned into two groups, one continued the same ARB and the other switched the ARB to irbesartan for 6 months.
|
30444137 |
2019 |
|
Hypertensive disease
|
0.070 |
Biomarker
|
group |
BEFREE |
The SGLT2 inhibitor and ARB Combination theRapy in pAtients with diabetes and uncontrolled nocturnal hypertension (SACRA) study investigated changes in blood pressure (BP) with empagliflozin plus existing antihypertensive therapy.
|
30586745 |
2018 |
|
Hypertensive disease
|
0.070 |
Biomarker
|
group |
BEFREE |
Crude regression analysis as well as adjusted for confounders (birth weight, pregnancy maternal smoking, gestational age, skin color, schooling, income, smoking, alcohol, physical activity, medical diagnosis of asthma, diabetes and hypertension, BMI, height, calcium intake, corticosteroid use, age at menarche, insulin and testosterone) were performed between the three biomarkers and the whole-body, lumbar spine and femoral BMD.
|
30501623 |
2018 |
|
Hypertensive disease
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II receptor blocker azilsartan medoxomil (AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) versus the ARB olmesartan (OLM) and the OLM fixed-dose combination with hydrochlorothiazide (OLM/HCTZ).
|
30217371 |
2018 |
|
Hypertensive disease
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Logistic regression analysis showed that the presence of Fx and of AH and the combination of the presence of Fx plus AH were associated with the H2 genotype regardless of the degree of cortisol secretion, age, BMI and BMD (OR 4.88, 95%CI 1.47-18.40, P = 0.05; OR 8.25, 95%CI 0.98-69.52, P = 0.05; OR 7.25, 95%CI 1.57-35.78, P = 0.011; respectively).
|
20584071 |
2010 |
|
Hypertensive disease
|
0.070 |
Biomarker
|
group |
BEFREE |
The results imply that the ARB agent, telmisartan, could treat both the hemodynamic and metabolic aberrations seen in subjects with the metabolic syndrome, such as insulin resistance, glucose intolerance, and hypertension.
|
16061040 |
2005 |